Department of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
J Gastrointest Surg. 2019 Oct;23(10):2100-2109. doi: 10.1007/s11605-019-04359-x. Epub 2019 Aug 13.
Although metastasis in lymph nodes along the left side of superior mesenteric artery (SMA-LNs-lt) is sometimes found, survival benefit of SMA-LN-lt dissection for pancreatic head cancer is still unclear. The purpose of this study is to evaluate the prognostic significance of SMA-LN-lt metastasis and micrometastasis.
A total of 166 patients with pancreatic head cancer who underwent pancreatectomy with lymphadenectomy including SMA-LNs-lt between 2002 and 2017 were reviewed retrospectively. Micrometastasis was evaluated by immunohistochemistry.
Twenty patients (12%) had SMA-LN-lt metastasis detected by hematoxylin and eosin (HE) staining, and eight patients (5%) had micrometastasis. Patients with SMA-LN-lt HE-positive or micrometastasis group experienced significantly shorter overall survival (OS) than those without (p = .015). In multivariate analysis, SMA-LN-lt HE-positive or micrometastasis (p = .034), portal vein resection (p = .002), histologic grade 2/3 (p = .046), LN metastasis (p = .002), and lack of adjuvant chemotherapy (p < .001) were independent risk factors. Within a subset of SMA-LN-lt HE-positive or micrometastasis group, lack of adjuvant chemotherapy (p = .003) was the independent poor prognostic factor.
In pancreatic head cancer, the rate of SMA-LN-lt HE-positive and micrometastasis was found in 12% and 5%, respectively. Adjuvant chemotherapy may contribute to improvement of prognosis in patients with LN metastasis including SMA-LN-lt metastasis and micrometastasis.
虽然沿肠系膜上动脉左侧(SMA-LN-lt)淋巴结转移有时会被发现,但对于胰头癌行 SMA-LN-lt 清扫术的生存获益仍不明确。本研究旨在评估 SMA-LN-lt 转移和微转移的预后意义。
回顾性分析了 2002 年至 2017 年间接受胰头癌切除术伴包括 SMA-LN-lt 在内的淋巴结清扫术的 166 例患者的资料。采用免疫组化法评估微转移。
20 例(12%)患者的 HE 染色显示 SMA-LN-lt 转移,8 例(5%)患者存在微转移。SMA-LN-lt HE 阳性或微转移组患者的总生存(OS)显著短于无转移组(p=0.015)。多因素分析显示,SMA-LN-lt HE 阳性或微转移(p=0.034)、门静脉切除(p=0.002)、组织学分级 2/3(p=0.046)、淋巴结转移(p=0.002)和缺乏辅助化疗(p<0.001)是独立的危险因素。在 SMA-LN-lt HE 阳性或微转移组的亚组中,缺乏辅助化疗(p=0.003)是独立的不良预后因素。
在胰头癌中,SMA-LN-lt HE 阳性和微转移的发生率分别为 12%和 5%。辅助化疗可能有助于改善包括 SMA-LN-lt 转移和微转移在内的淋巴结转移患者的预后。